MONROVIA, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today the closing of the previously announced underwritten public offering of 1,999,850 shares of its common stock, which includes the full exercise of the underwriter’s option to purchase up to an additional 260,850 shares, at a price to the public of $39.00 per share. The gross proceeds of the offering, before deducting underwriting commissions and offering expenses, were $77,994,150. Canaccord Genuity acted as the sole book-running manager for the offering.
All shares of the common stock offered by STAAR were offered pursuant to an effective shelf registration statement (including a prospectus) on Form S-3 previously filed with the Securities and Exchange Commission (“SEC”). Copies of the prospectus supplement and base prospectus relating to the offering may be obtained from Canaccord Genuity LLC, Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, toll-free phone: 1-800-225-6201 or by e-mail at prospectus@canaccordgenuity.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
